SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs anticipated Phase 3 REGAL topline results for its GPS leukemia treatment, a binary catalyst that has traders weighing hopes for a positive readout against concerns about trial failure. The debate is intensified by sharp price swings, with bullish claims of short pressure and manipulation contested by skeptics who see the outcome as uncertain.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported preliminary takeover discussions involving Silver Lake and Saudi Arabias PIF are fueling attention, though traders debate whether the valuation discussed is too low and whether a deal will happen. The speculation comes alongside Unitys strong Q3 results, first GAAP-profitable quarter, and rapid Vector ad growth, which some traders argue support the companys standalone value.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA decision on ivonescimab for EGFR-mutated lung cancer is the dominant focus, with traders weighing strong progression-free-survival results and encouraging overall-survival trends against the FDAs stated need for statistically significant overall-survival evidence. The community is split between approval hopes and concerns about a rejection or delay, driving anxious, volatile positioning around the binary outcome.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Heavy trading and a sharp move have reignited speculation about a potential Big Pharma partnership or buyout, with Novo often named as a possible counterparty; no deal is confirmed. Traders are divided between seeing the activity as positioning around VK2735 and upcoming obesity-conference presentations and dismissing it as another rumor-driven pump amid a long wait for Phase 3 results.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure and uncertainty over Nvidias next CEO are driving debate, with traders weighing reports that the board approached Arm CEO Rene Haas against speculation Huang could return. Bulls view the selloff as a buying opportunity, while bears point to leadership uncertainty and unresolved China-related export scrutiny as risks.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly performance and raised outlook, attributed in the discussion to robust oral Wegovy demand, have fueled renewed interest in the shares. Bulls see the pill and international expansion as growth drivers, while skeptics point to Lillys competition, pricing pressure and execution concerns.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

The CHMP reaffirmed its negative recommendation on EU marketing authorization for Zevras Miplyffa, triggering a sharp selloff. Traders disagree on whether the drop is an overreaction to an expected setback, with bullish voices pointing to the drugs existing U.S. approval and commercial business while critics question management and Europes prospects.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians persistent share-price weakness and choppy trading dominate discussion, with traders attributing pressure to short-selling or options activityclaims that remain speculative. Bulls point to Q3 progress, R2 recognition and the upcoming Autonomy & AI Day, while skeptics focus on cash burn, profitability and management execution.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

A softer-than-expected monthly PPI reading is being weighed against accelerating year-over-year producer inflation, keeping traders focused on possible Fed rate hikes and elevated Treasury yields that pressure TLT. The community is split between expecting further bond weakness and viewing a recession or eventual rate cuts as a longer-term tailwind.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

Record Q3 results and raised full-year guidance have drawn attention, with traders pointing to international contract growth and demand for HawkEye 360s defense and signals-intelligence services. Sentiment is largely bullish around the strong share move and trading volume, while claims of institutional accumulation remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pilbara Gold Ltd. engages in mining and exploration of resources. Its projects include Mt York Gold Project in the Pilbara and its Roe Hills Gold Project, in the Kalgoorlie area, Western Australia. The company was founded on August 16, 1983 and is headquartered in West Perth, Australia.

Pilbara Gold Ltd.

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.255
Prev Close	$0.2794
Open	$0.255
Dividend Yield	0.00%
50-Day Moving Average	$0.3368
Beta	-4.93
Avg. Volume	21,166.14
PE Ratio	-27.67

52-Week High	$0.5656
52-Week Low	$0.001
Market Capitalization	$65.4M
EPS (Annual)	-$0.0104
Price to Book	1.83
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

KAIFF Fundamentals